Highlights from the Big Pharma Report posted on AOL's Motley Fool Pfizer Board.
Have PFun!
BigKNY3
_____________________________________________
Big Pharma Report- 2/21/98
Week
Big Pharma continued its momentum with a 1.2% gain as compared to increases for the record Dow (+0.5%), the record S&P (+1.3%) and the almost record NAStie (+1.0%). Five of the "Healthy 13" set all-time highs; SGP (78.88), MRK (124.94), PFE (88.25), ABT (75.75), and JNJ (70.56).
MRK (+5.9%) was the weekly leader amid hopes for the near-term approval of its asthma medication Singulair and notification of priority review for Aggrastat for unstable angina.
PFE (+4.4%) rose on the announcement of its marketing partnership with Searle for Celebra.
WLA (-2.9%) and LLY (-2.7%) were the major laggards in Big Pharma. LLY bounced off a low of 59 1/2 on news that Evista new Rx's "were running behind early weeks for Fosamax".
February 1998
After the strong January (+10.7%), Big Pharma (+2.5%) continues to trail the February gains for the Dow (+6.4%) S&P (+5.5%) and the NASTie (+6.7%). GLX (+16.6%) leads the month as merger talks with SBH (+5.0%) continue. AMGN (+8.5%) is starting to bounce.
PFE (+6.8%) is ranked 4th for the month ..but on the move.
LLY cups the cellar (-8.8%).
YTD 1998
Big Pharma (+13.5%) continues to double the Dow (+6.4%), the S&P (+6.6%) and outgains the NAStie (+10.0%).
GLX (+31.1%) has regained the YTD lead from its soon to be partner SBH (+28.8%). Last year's champ SGP is showing amazing staying power (+24.7%). AMER (+24.7%) is third for no apparent rationale reason. Powerhouses MRK (+17.6%) and PFE (+17.1%) are making their moves.
LLY (-11.0%) is the only Big Pharma showing a YTD decline.
Big Pharma News You Can Use (BigKNY3 Comments)
-Barrons lead article reports that guru Abby Cohen remains very bullish.
-Gruntal reiterated a strong buy on MRK and upped its target price to 150.
-The Right Line Split Report predicts that MRK will announce a 2-1 split on 2/25/98. Historically MRK splits 3-1 at higher levels.
--The Wall Street Transcript issued a special issue on healthcare stocks. Some PFE highlights:
-"PFE is the best out there. I see PFE as the MRK of the 90s. PFE proved that through strong focus on support of research."
-"PFE is the one company that has a more balanced approach towards the industry. It's not just focused on developing newer drugs,but also on marketing them effectively. I don't think any company does it better than PFE."
-Medical Marketing and Media has issued an industry outlook for 1998. General comment: "Smooth sailing ahead". Products to watch in 1998 are Evista (LLY), Viagra (PFE), Propecia (MRK), Plavik (BMY), Detrusitol (PNU), and Citalopram (Forest Labs).
-The agreement between Monsanto and PFE for Celebra was no surprise to the PFEr Board. Here is a bulleted highlight from the 2/7/98 Big Pharma Report: -Business Week is highlighting the Cox-2s from MTC and MRK. PFE or LLY could become the marketing partner for MTC (Searle).
-The first stock recommended on Wall Street Week last night was PFE by Martin Zweig: "I like to buy strength. I like to go with the trend. The trend is your friend."
ED News You Can Use (BigKNY3 Comments)
--V Day Countdown: -38 Days |
